The solid centre line in the boxplot represents the median and the diamond the geometric mean, the bounds of the box the 25 th and 75 th interquartile ranges, whiskers display the 1.5 interquartile ranges, and dots the outliers. a IgG concentrations after vaccination with RTS,S/AS01E by age cohort. b IgG concentrations after vaccination with RTS,S/AS01E by site. c IgG concentrations before vaccination by age cohort. d IgG concentrations before vaccination by site. Groups were compared by t-tests.
Supplementary Figure 1 a

RTS,S/AS01E
Comparator 706 were studied 416 children and 290 infants 1,078 had plasma/serum 566 children and 512 infants 539 had plasma/serum 285 children and 254 infants 322 were studied 203 children and 119 infants -3 subjects were excluded in Kintampo because had insufficient plasma -305 out of a total of 674 subjects were sampled in Nanoro for the study 533 had pre-vaccination sample 284 children and 249 infants 231 had pre-vaccination sample 132 children and 99 infants 1,678 subjects were included in the M067 modified ATP criteria cohort 1,805 subjects were included in the M067 ITT cohort 4,319 subjects enrolled in the intention to treat (ITT) Phase 3 RTS,S Trial (M055) for Bagamoyo, Kintampo and Nanoro -1 did not meet inclusion criteria -126 excluded because: 3 did not receive 3 vaccine doses 75 did not adhere to the primary vaccination schedule 1 pre-vaccination temperature ≥ 37.5ºC 44 did not comply with blood collection schedules 3 other reasons -4 subjects were excluded in Kintampo because had insufficient plasma -140 out of a total of 353 subjects were sampled in Nanoro for the study
The solid centre line in the boxplot represents the median and the diamond the geometric mean, the bounds of the box the 25 th and 75 th interquartile ranges, whiskers display the 1.5 interquartile ranges, and dots the outliers. a IgG concentrations after vaccination with RTS,S/AS01E by age cohort. b IgG concentrations after vaccination with RTS,S/AS01E by site. c IgG concentrations before vaccination by age cohort. d IgG concentrations before vaccination by site. Groups were compared by t-tests.
• and between M0 and M3-M0 difference in IgG concentrations. In all subjects, M0 vs M3 correlations: a CSP NANP, 5-17 months old children (n = 276 matched M0 and M3); b CSP NANP, 6-12 weeks old infants (n = 246); c CSP C-terminus (C-term), 5-17 months old children (n = 279); d CSP C-term, 6-12 weeks old infants (n = 249), with the Spearman correlation coefficients (rho). Stratified by age (children age 5-17 months and infants age 6-12 weeks), site and vaccination status, M0 vs M3 correlations: e CSP NANP; f CSP C-term, with linear regression (blue line), non-parametric LOESS estimation (red line) and diagonal line (y=x) (black solid line). Stratified by age in RTS,S vaccinees, M0 vs M3-M0 correlations: g CSP NANP; h CSP C-term, with simple linear regressions with the strength (coefficient for the slope of the line) and significance of associations shown in the figures as well as the correlation coefficients (rho). The distribution of subjects with both time points was compared with those with only one (M0 or only M3). 272 (26.4%) out of all participants had only one visit sample; 265 (97.4%) had only M3, and 7 (2.57%) only M0. When comparing these subjects with the ones with both time points, no statistically significant differences were found with respect vaccination status (p = 0.408) and concentration values at M0 (p=0.076) overall for both antigens. With regards age cohort (p <0.001), site (p <0.001), and M3 concentration values (p<0.001), statistically differences were found, being those with only one visit older, mainly from Bagamoyo, and with higher M3 concentration. The plot legends show the median survival time (days), i.e., time at which the survivorship function equals 0.5, for each antibody tertile with the corresponding 95% confidence interval and the p-values assessing differences in the distribution of survival time across the three strata in each of the four subgroups (estimated through the Log-rank test). . Kaplan-Meier curves with IgG (log 10 EU mL -1 ) and AI (log 10 AI) stratified in tertiles (t3 = highest, t2 = moderate, t3 = lowest). P-values were obtained through log-rank tests. 
Season malaria transmission
Low or no Factors affecting RTS,S/AS01E immunogenicity. Relevant demographic, clinical and epidemiological factors associated with vaccine-induced IgG concentration (EU mL -1 ) measured in log 10 scale. Coefficients and 95% confidence intervals (CI). In bold font values that are statistical significance based on 95% CI not including zero. Previous episodes refer to having had clinical malaria episodes during the vaccination period (between month 0 [M0] and M3). Season of malaria transmission refers to the period when the post-vaccination sample was collected. WAZ: weight-for-age Z-score; HAZ: height-for-age Z-score. . This means the risk in Nanoro over Bagamoyo is 5x higher at day1 but this risks increases with time up to 180 days. Below, at 180 days Nanoro has more risk than Bagamoyo, but the magnitude decreases because the risk at 180 days (2,202) decreases having days into account at a rate of 0.98. I.e. at 180 days the HR is 2,202 * 0.98^180.
Supplementary
Supplementary Methods
Subject and sample selection. Individuals considered eligible for the study were those from the according to protocol (ATP) MAL067 cohort who had 75 µl of M3 plasma/serum sample stored. The ATP criteria included receiving 3 doses of vaccine, and having a blood sample collected approximately 30 days after vaccination (M3). In Kintampo (n= 311, 148 children and 163 infants) and Bagamoyo (n=272 children) all eligible children were selected, and in Nanoro, 445 participants (199 children and 246 infants) were randomly selected (Table 1 and Supplementary Figure 1) . Nearly all subjects in Kintampo (100%) and Bagamoyo (99%) had pre-vaccination (M0) samples available, while in Nanoro, only 41% subjects, all infants, had M0 samples.
Subject follow up. Subjects were followed up by passive case detection (PCD) starting 14 days from the date of sample collection to ascertain that antibody responses measured would be predictive of a future malaria episode and not markers of past malaria infection. The follow-up for clinical malaria events in this study was defined for the subsequent 12 months, during which subjects were visited monthly to also assess whether they were still living in the study area and participating in the study. After the 12 months of follow up, subjects were censored. Reasons for early termination were recorded.
ELISA data pre-processing. ELISA data were captured using Magellan software (TECAN, Switzerland). The standard curves were estimated using a 4-parameter logistic (4PL) regression and were fitted after averaging the optical density (OD) of the standard points replicates. To provide EU mL -1 data in the absence of an international standard, the curves were pre-calibrated at IAVI-HIL by determining an average reciprocal of dilution for each monoclonal antibody that provided an OD=1 (12,114 EU mL -1 and 6,966 EU mL -1 for CSP C-term and NANP, respectively). Sample IgG concentrations (EU mL -1 ) were interpolated from the 4PL standard curve using the OD of the lowest dilution in the linear section of the curve (under the upper limit of detection). The replicates of the test samples were averaged and used as the test sample measurement. Quality control for each plate was based on positive, negative, and blank controls. A plate was considered to fail based on: i) thresholds for blank and negative controls and Westgard rules for positive controls; ii) expected standard curve characteristics. A sample was considered to fail based on: i) replicates variability; ii) high IgG titre requiring additional dilution to fall on the linear section of the 4PL curve (above 1:7,200).
Using a uniform distribution, the non-quantitated ELISA concentration data were imputed using values between limit of detection (LOD) and limit of quantification (LOQ), provided by IAVI-HIL. To account for the correlation between avidity concentration and ELISA concentration data, the imputed values of the avidity samples were generated given the ELISA values, imputed or observed (whether quantitated or not) by fitting a model with the OD of the non-quantitated samples. This model was fitted using generalized least squares models (GLS). Using the original ODs we maintained the correlation structure between ELISA and avidity data, and by fitting a GLS model we accounted for the heteroscedasticity of the data. The avidity ODs were fitted using as a predictor the OD of the imputed (or observed) ELISA after converting the imputed (or observed) concentration in OD (using a randomly selected standard curve from all assayed plates). To convert the imputed avidity OD into concentration we used the same standard curve used to convert imputed ELISA concentrations to ODs. The GLS models were antigen-specific, type of non-quantitated data-specific (i.e., whether it was avidity or not) and were validated by inspecting the residuals distribution and comparing the correlation structure between the original OD of the data and the imputed one (Supplementary Tables 4 and 5) . Tables contain information on how many values were imputed and how many measured.
Immunogenicity data analysis. Mixed linear models were fit including as outcomes M3 and M0 anti-NANP and M3 and M0 anti-C-term CSP IgG concentrations, as well as vaccination, time point, and the appropriate interaction. Necessity of including a random slope for changes over time was assessed during model building through exploratory analysis (trajectory plots) and statistical tests, i.e., ANOVA test comparing two models: i) those with random intercept and random slope, and ii) those with only random intercept. The main mixed model equation, without any other adjusted covariate, used in the analysis was expressed as follows:
∼ ! + ! * 3 + ! * , + ! * 3 , + ( / ) Where ( / ) defines the random intercepts per subject and random slope M3-M0. Using this notation we were able to estimate the concentration, for example, for the M3-RTS,S cohort as ( ! + ! + ! + ! ) and for the M0-RTS,S cohort as ( ! + ! + ! ), being the concentration difference between both timepoints M3-M0 for RTS,S cohort equal to ! . After linearity of associations with continuous covariates was evaluated, parametric generalized linear models (GLM) were fit and non-linear terms were included as b-splines with degrees of freedom estimated for the spline term in the generalized additive models (GAM) model 1 . In models including relevant covariates, an adjusted effect of vaccination was evaluated and the impact of these covariates on immunogenicity was assessed through interaction terms. Covariates were retained in models based on statistical significance association with outcomes, and on their impact on the correlate coefficients.
